Saluda Medical Expands U.S. Growth Potential with FDA Clearance for CAP24 Paddle Lead
Saluda Medical, Inc (ASX: SLD) has achieved an important regulatory milestone after securing U.S. FDA clearance for its CAP24 surgical paddle lead, strengthening its position in the spinal cord stimulation market. The approval allows the company to offer its Evoke System with EVA Sensing Technology for surgical paddle lead procedures, extending its presence beyond its existing percutaneous product range. This development creates new opportunities to serve neurosurgeons and orthopedic surgeons, a segment responsible for a significant share of spinal cord stimulation procedures across the United States. The company plans to introduce the product through a phased launch in the second half of 2026 before expanding commercial availability as clinician training and inventory increase. Purpose-built for closed-loop neuromodulation, the CAP24 lead continuously responds to patient neural activity to improve therapy delivery. The approval broadens Saluda Medical's commercial opportunities, supports future revenue growth, and reinforces its commitment to advancing innovative treatments for chronic neurological conditions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Saluda Medical Expands U.S. Growth Potential with FDA Clearance for CAP24 Paddle Lead
Saluda Medical, Inc (ASX: SLD) has achieved an important regulatory milestone after securing U.S. FDA clearance for its CAP24 surgical paddle lead, strengthening its position in the spinal cord stimulation market. The approval allows the company to offer its Evoke System with EVA Sensing Technology for surgical paddle lead procedures, extending its presence beyond its existing percutaneous product range. This development creates new opportunities to serve neurosurgeons and orthopedic surgeons, a segment responsible for a significant share of spinal cord stimulation procedures across the United States. The company plans to introduce the product through a phased launch in the second half of 2026 before expanding commercial availability as clinician training and inventory increase. Purpose-built for closed-loop neuromodulation, the CAP24 lead continuously responds to patient neural activity to improve therapy delivery. The approval broadens Saluda Medical's commercial opportunities, supports future revenue growth, and reinforces its commitment to advancing innovative treatments for chronic neurological conditions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au